{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:28:44Z","timestamp":1793694524326,"version":"4.5.1"},"reference-count":23,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2025,8,27]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Few rifampicin-resistant TB (RR-TB) studies show pre-treatment outcomes and definitive treatment outcomes (accounting for RR-TB re-treatment). Our Niger countrywide study covered 15 years to show the trend of RR-TB diagnoses, time-to-treatment initiation, and pre-and on-treatment attrition (loss to follow-up or death).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Retrospective study including all Niger RR-TB patients diagnosed between 2008 and 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      872 RR-TB patients were diagnosed, 725 (83.1%) started treatment, and 32 required retreatment. Between 2008 and 2013 (phenotypic testing), 2014 and 2018 (regional molecular testing), and 2019 and 2022 (decentralised molecular testing), the annual average first RR-TB treatment initiations increased from 22 to 50 and 85, and the median time to first RR-TB treatment reduced from 260 to 17 and 11 days, by period. Pre-treatment attrition reduced from 34.1% to 12.8% and 12.6%. On-treatment attrition increased from 8.8% to 13.5% and 19.8%. Overall, 81.7% (\n                      <jats:italic>N<\/jats:italic>\n                      = 725) experienced definitive treatment success. On-treatment attrition was 18.3%, predicted by older age, female gender, low BMI, RR-TB\/HIV co-infection, high baseline bacillary load, and treatment initiation between 2019 and 2022.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In Niger, over 15 years of RR-TB control, pre-treatment attrition reduced over time, reflecting better access to care. Treatment success was high, exceeding global success. However, increasing on-treatment attrition should be addressed by targeting high-risk groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/ijtldopen.25.0455","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:57:27Z","timestamp":1768471047000},"page":"4-10","source":"Crossref","is-referenced-by-count":1,"title":["Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success"],"prefix":"10.5588","volume":"3","author":[{"given":"I.","family":"Maman Lawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Souleymane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Soumana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Aboubacar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hamissou Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Kabirou Amoussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hamidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hamidou Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Adamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Adehossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mamadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Catherine de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rigouts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lorent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Doutchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Piubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2026,1,1]]},"reference":[{"key":"2026031812065783000_3.1.4.1","unstructured":"World Health Organizaton . Global tuberculosis report. Geneva: WHO, 2023."},{"key":"2026031812065783000_3.1.4.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0077OC"},{"key":"2026031812065783000_3.1.4.3","unstructured":"World Health Organizaton . WHO consolidated guidelines on tuberculosis module 4: treatment drug-resistant tuberculosis treatment 2022 update. Geneva: WHO, 2022."},{"key":"2026031812065783000_3.1.4.4","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0075"},{"key":"2026031812065783000_3.1.4.5","doi-asserted-by":"crossref","first-page":"105844","DOI":"10.1016\/j.rmed.2019.105844","article-title":"Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: aationwide programmatic achievements","volume":"161","author":"Piubello","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"2026031812065783000_3.1.4.6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4269\/ajtmh.20-1361","article-title":"Predictors of rifampicin-resistant tuberculosis mortality among hiv-coinfected patients in Rwanda","volume":"105","author":"Habimana","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2026031812065783000_3.1.4.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2019-002280"},{"issue":"1","key":"2026031812065783000_3.1.4.8","doi-asserted-by":"crossref","first-page":"e015977","DOI":"10.1136\/bmjgh-2024-015977","article-title":"Pretreatment attrition after rifampicin-resistant tuberculosis diagnosis with Xpert MTB\/RIF or ultra in high TB burden countries: a systematic review and meta-analysis","volume":"10","author":"Jouego","year":"2025","journal-title":"BMJ Glob Health"},{"key":"2026031812065783000_3.1.4.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00498-X"},{"issue":"10","key":"2026031812065783000_3.1.4.10","doi-asserted-by":"crossref","first-page":"e0205463","DOI":"10.1371\/journal.pone.0205463","article-title":"High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa","volume":"13","author":"Hirasen","year":"2018","journal-title":"PLoS One"},{"key":"2026031812065783000_3.1.4.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006914"},{"issue":"5","key":"2026031812065783000_3.1.4.12","doi-asserted-by":"crossref","first-page":"e0250804","DOI":"10.1371\/journal.pone.0250804","article-title":"Predictors of mortality and loss to follow-up among drug resistant tuberculosis patients in Oromia Hospitals, Ethiopia: a retrospective follow-up study","volume":"16","author":"Woldeyohannes","year":"2021","journal-title":"PLoS One"},{"key":"2026031812065783000_3.1.4.13","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1017\/S0950268820002514","article-title":"Predictors of mortality among multidrug-resistant tuberculosis patients in central Ethiopia; a retrospective follow-up study","volume":"148","author":"Kassa","year":"2020","journal-title":"Epidemiol Infect"},{"key":"2026031812065783000_3.1.4.14","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJID.2020.05.087"},{"issue":"4","key":"2026031812065783000_3.1.4.15","doi-asserted-by":"crossref","first-page":"e0230848","DOI":"10.1371\/journal.pone.0230848","article-title":"Treatment outcomes of multi drug resistant and rifampicin resistant tuberculosis in Zimbabwe: a cohort analysis of patients initiated on treatment during 2010 to 2015","volume":"15","author":"Matambo","year":"2020","journal-title":"PLoS One"},{"key":"2026031812065783000_3.1.4.16","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e33"},{"issue":"4","key":"2026031812065783000_3.1.4.17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5588\/ijtld.22.0638","article-title":"Unfavorable treatment outcomes among patients with drug-resistant TB in Uganda","volume":"27","author":"Kintu","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"2026031812065783000_3.1.4.18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciy066","article-title":"Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up","volume":"67","author":"Yu","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2026031812065783000_3.1.4.19","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/cid\/ciac322","article-title":"Low body mass index at treatment initiation and rifampicin-resistant tuberculosis treatment outcomes: an individual participant data meta-analysis","volume":"75","author":"Campbell","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031812065783000_3.1.4.20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031574"},{"issue":"1","key":"2026031812065783000_3.1.4.21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12879-021-06992-x","article-title":"Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: a retrospective cohort study","volume":"22","author":"Wrohan","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2026031812065783000_3.1.4.22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/inthealth\/ihz005","article-title":"Effect of reliance on Xpert MTB\/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study","volume":"11","author":"Mollel","year":"2019","journal-title":"Int Health"},{"key":"2026031812065783000_3.1.4.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02250-2020"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.25.0455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T19:07:15Z","timestamp":1773860835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.25.0455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.5588\/ijtldopen.25.0455"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.25.0455","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}